Ozempic Pen Information Disclaimer

Please note that we do not distribute or sell Ozempic Pen. The content provided on this webpage is intended solely for informational and educational purposes. It should not be construed as medical advice, diagnosis, or treatment recommendation. Always consult a qualified healthcare professional for personalised medical advice and treatment options.

Treatment options

Ozempic Pen - welzo
Ozempic Pen - welzo

Ozempic Pen

Ozempic Pen - welzo
Ozempic Pen - welzo
£200.00
Sale price £200.00

Medication features

  • Not licensed for weight loss in the UK
  • Read more

Medication features

  • Not licensed for weight loss in the UK
  • We do not offer Ozempic
  • Usage can impact critical supply for Diabetic patients
  • Wegovy is a direct alternative

Ozempic Weight Loss Injection in the UK

We do not supply Ozempic as a weight loss solution due to its current licensing only for type 2 diabetes treatment in the UK. Our dedication to ethical practice also steers us away from providing treatments that could potentially lead to shortages, impacting those who rely on this medication for diabetes management.

However, we are excited to introduce alternative weight loss injections available at our platform, which are also based on similar active ingredients as Ozempic. Wegovy, a new release expected in mid-2023, contains the same active ingredient as Ozempic—semaglutide—and is licensed and specialized for weight loss. Additionally, it simplifies administration of the recommended dosages to maximize benefits.

Saxenda, another offering from our portfolio, is also a GLP-1 agonist like Ozempic and Wegovy, and helps in suppressing appetite when injected subcutaneously daily.

To stay informed on the availability of Wegovy upon its release, please subscribe to our mailing list.

Ozempic Overview:

Ozempic, containing the active ingredient semaglutide, is a licensed medication in the UK designed primarily for treating type 2 diabetes by assisting the body in managing high blood sugar levels, thus reducing risks associated with diabetic complications such as heart disease. Its administration involves weekly injections with a dose gradually increased over 4-8 weeks until the maintenance dose is reached.

Usage for Weight Loss:

Semaglutide, resembling a natural hormone, GLP-1, is pivotal in appetite regulation, aiding individuals in feeling fuller, which can lead to reduced food intake and weight loss.

Side Effects:

For full information on Ozempic side effects click here.

While utilizing Ozempic for diabetes treatment, users may experience side effects including, but not limited to, nausea, diarrhea, vomiting, bloating, and tiredness, with severe cases involving inflamed pancreas (acute pancreatitis) demanding immediate medical attention. For extensive information on side effects, refer to section 4 of the patient information leaflet provided with the medicine.

Availability on NHS:

While Ozempic is procurable through NHS for diabetes treatment, it is not currently dispensed as a weight loss medication by NHS. For weight loss, it is accessible through private prescriptions from private clinics, with costs varying significantly. Orlistat is an alternative weight loss treatment available on the NHS and over the counter at local pharmacies.

Due to a global shortage in the supply of all GLP-1 agonists such as Ozempic, we are unable to initiate treatment for new customers. We are only able to continue with the treatment for our existing customers. We sincerely apologise for any inconvenience this may cause you.